1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Asthma And COPD Drugs Market
2.2. Global Asthma And COPD Drugs Market, By Drug, 2023 (US$ Million)
2.3. Global Asthma And COPD Drugs Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Asthma And COPD Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Asthma And COPD Drugs Market Vendors
3.2. Strategies Adopted by Asthma And COPD Drugs Market Vendors
3.3. Key Industry Strategies
4. Asthma And COPD Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Asthma And COPD Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Anti-inflammatory drugs
5.3.1.1. Corticosteroids
5.3.1.2. Anti-Leukotrienes
5.3.1.3. Monoclonal antibodies
5.3.2. Bronchodilator monotherapy
5.3.2.1. Short-acting beta2-agonist (SABAs)
5.3.2.2. Long-acting beta2-agonist (LABAs)
5.3.2.3. Anticholinergics
5.3.3. Combination drugs
5.3.4. Pipeline Analysis
5.3.4.1. Projected sales of Phase III Asthma/COPD Drugs estimated till 2029 (US$ Mn)
5.3.4.1.1. GSK/INNOVIVA Fluticasone Furoate + Umeclidinium + Vilanterol (COPD)
5.3.4.1.2. Novartis Fevipiprant (Asthma)
5.3.4.1.3. Astrazeneca Tralokinumab (Asthma)
5.3.4.1.4. AstraZeneca/Kyowa Hakko Kirin Benralizumab (Asthma)
5.3.4.1.5. AstraZeneca Budesonide + formoterol (COPD)
5.3.4.1.6. AstraZeneca Budesonide + formoterol + glycopyrrolate (COPD)
5.3.4.1.7. AB Science Masitinib (Asthma)
5.3.4.1.8. GlaxoSmithKline Vilanterol (COPD)
5.3.4.1.9. Regeneron/Sanofi Dupilumab (Asthma)
5.3.4.1.10. Sunovion Sun-101(COPD)
5.3.4.1.11. Theravance Biopharma/Mylan Revefenacin (COPD)
5.3.4.1.12. Others
5.3.4.2. Tabular Representation of Phase II and I Drugs


6. North America Asthma And COPD Drugs Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.Asthma And COPD Drugs Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Asthma And COPD Drugs Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.Asthma And COPD Drugs Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Asthma And COPD Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.Asthma And COPD Drugs Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)

9. Latin America Asthma And COPD Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.Asthma And COPD Drugs Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Asthma And COPD Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.Asthma And COPD Drugs Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Asthma And COPD Drugs Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. Novartis AG
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Merck & Co
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Glaxosmithkline Plc
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Boehringer Ingelheim Gmbh
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Nycomed
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Abbott Laboratories
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. AstraZeneca
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Roche Holding AG
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Teva Pharmaceutical Industries
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Vectura Group
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Pfizer Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives